Letters to the Editor
Transparency of drug information
- Christophe Kopp
- Aust Prescr 2006;29:59-62
- 1 June 2006
- DOI: 10.18773/austprescr.2006.040
The Editorial Executive Committee welcomes letters, which should be less than 250 words. Before a decision to publish is made, letters which refer to a published article may be sent to the author for a response. Any letter may be sent to an expert for comment. When letters are published, they are usually accompanied in the same issue by their responses or comments. The Committee screens out discourteous, inaccurate or libellous statements. The letters are sub-edited before publication. Authors are required to declare any conflicts of interest. The Committee's decision on publication is final.
Editor, – We have tried to emulate your T-score (Aust Prescr 2005;28:103) in our French drug bulletin, la revue Prescrire, in order to expose pharmaceutical companies' readiness to respond to our requests for information on their products.
Our rating system is similar to yours, but it specifies the provision of unpublished data and packaging information. We presented our rating system in January this year during our Pill Awards, a ceremony which recognises new drugs which have genuine benefits.
We wish you all the best with your T-score, and hope our approach will also improve access to key data. Thanks for showing the lead!
1 - manufacturer provided detailed information, including unpublished data and packaging items
2 - manufacturer provided information limited to administrative and published data
3 - manufacturer provided minimal information, mainly administrative data
4 - manufacturer provided no information
Managing Editor, Prescrire International Paris, France